ABX · Abacus Global Management, Inc. · Stock research

Current Thesis

The binary that framed the July note has resolved, and the resolution went the wrong way for the narrative even though it went the right way for the numbers. Q2 2026 (reported 2026-08-06) beat on every line management guides to: revenue $73.020M against a $66.088M consensus, adjusted diluted EPS $0.28 against a $0.24 estimate and above the top of the $0.24–0.26 guide, FY2026 adjusted EPS affirmed at $1.00–1.05 versus $0.99 consensus, Q3 guided $0.26–0.28 versus $0.27. Piper Sandler responded on 2026-08-07 by holding Neutral and cutting its target to $12 from $13. The board authorized a $100M repurchase program on 2026-08-13, commencing 2026-08-17. Through all of it the tape went one way: the last completed daily close was $9.27 on 2026-08-14, 22.8% below the 52-week high of $12.00 on the adjusted series, RSI(14) 36.4, three-month return +2.0%. The RWA-tokenization re-rating leg an investor was buying in July — 100+ policies on-chain, a $224B secondary-market TAM, announced 2026-07-07 — is the leg that has stopped paying. What remains is a fee-and-spread business compounding revenue ~30% with a widening gap between adjusted and GAAP earnings, trading below the shelf that defined its uptrend.

The narrative is dead for the tokenization re-rating leg, dated by four events that each failed to produce price — the 2026-07-07 announcement that marked the $12.44 raw high and reversed 7.34% to $11.11 by 2026-07-10; the 2026-08-06 beat-and-affirm; the 2026-08-13 buyback authorization; and the 2026-08-14 close at $9.27, below the $10 area the prior frame identified as the structural line. This labels the narrative and the price structure. It is not a claim about the operating business, which is growing.

Bullish and bearish views on Abacus Global Management, Inc.

The model's bull view on Abacus Global Management, Inc. (ABX), in brief: Q2 2026 (2026-08-06): revenue $73.020M, +29.9% YoY, versus $66.088M consensus; adjusted net income $27.1M versus $21.9M a year earlier; adjusted EBITDA ~$40M, +27% YoY, above the company's own guidance. The bear view: GAAP deteriorated while adjusted improved. Both cases follow in full.

Bull Case

• Q2 2026 (2026-08-06): revenue $73.020M, +29.9% YoY, versus $66.088M consensus; adjusted net income $27.1M versus $21.9M a year earlier; adjusted EBITDA ~$40M, +27% YoY, above the company's own guidance.
• Guidance held rather than reset: FY2026 adjusted EPS affirmed $1.00–1.05 against $0.99 consensus; Q3 guided $0.26–0.28 against $0.27 (both 2026-08-06). Management did not use a strong quarter to build a cushion, and did not cut.
• Fee-capital formation is the cleanest number in the release: longevity funds took in $544.2M in H1 2026, past the full-year $500M target and approaching the $604M raised in all of 2025. Third-party capital carries different revenue quality than balance-sheet policy marks.
• Capital return re-armed into weakness: $100M repurchase authorized 2026-08-13 and commencing 2026-08-17, on top of roughly $80M repurchased under prior programs since December 2023.
• Analyst dispersion is wide and skews high: B. Riley's Timothy D'Agostino is reported (TipRanks/The Fly, 2026-08-07) to have raised his target to $16 from $15 with a Buy, against Piper Sandler's Neutral and $12 the same week. Six-analyst consensus is reported near $13.6 average with a $10 low.
• Litigation moved from overhang toward optionality: the 2026-08-04 update states the court found the claims plausibly allege a scheme to harm the company, after the 2026-06-26 denial of Coventry's motion to dismiss; depositions are underway.

Bear Case

• GAAP deteriorated while adjusted improved. Q2 net income attributable to common shareholders was $6.6M versus $17.6M a year earlier (−63%); diluted GAAP EPS $0.07; operating profit $21.5M, −4.6% YoY. Adjusted net income $27.1M against $6.6M GAAP is a wider spread than Q1's $20.1M against $7.3M.
• The reaction, not the report, is the datapoint: a beat, an affirmed FY guide and a $100M authorization arrived inside eight sessions and the stock still closed $9.27 on 2026-08-14. A +2.0% three-month return means the spring advance has round-tripped.
• Piper Sandler's target path — raised to $13 on 2026-07-13, cut to $12 on 2026-08-07, Neutral throughout — is a sell-side that keeps marking the model without endorsing the story.
• Tokenization remains announced and unmonetized. No revenue has been attached to it, no custody or institutional partner has been named, and the year-end 2026 full-portfolio target is now roughly four months out with no interim milestone disclosed.
• Insider supply into the print: Simply Wall St flagged an on-market sale by Kevin Kirby of roughly 38,000 shares at about $10.31 on 2026-08-03, three sessions before earnings, described as under 1% of the direct holding.
• Life-settlement carrying values are mark-to-model on actuarial assumptions. A widening adjusted-to-GAAP spread in a book valued this way invites scrutiny of stated book value, and that scrutiny tends to arrive when the multiple is already compressing.

Setup & Price Structure

• Reference: $9.27 close, 2026-08-14. 52-week high $12.00 on the split/dividend-adjusted series (the raw July print was $12.44); distance from high −22.8%.
• RSI(14) at 36.4 is weak without being washed out — no sub-30 capitulation reading to lean on.
• The $10 area named in the prior frame as the year-long uptrend shelf gave way after the print. Until a weekly close reclaims it, the structure is lower highs from 2026-07-07 and lower lows.
• Confirmation, if it comes, looks like a higher low followed by a weekly close back above $10.50 — an actual base, not one green session on buyback-program headlines.
• Crowding and positioning observables: price sits below its recent averages rather than extended above a rising one; RSI 36.4 and a −22.8% drawdown are the opposite of a crowded-long condition. The earnings binary is behind, not ahead — the next print falls outside 30 days. There is no visible retail-sentiment clustering around the name and no equity issuance into strength disclosed; the flow event in the window runs the other way, with the company itself the marginal buyer from 2026-08-17. The one supply datapoint is the reported 2026-08-03 insider sale near $10.31.

Catalyst Calendar (next 30 days)

• ~2026-11 (est.) — Q3 2026 print against the $0.26–0.28 adjusted-EPS guide. Outside the 30-day window; nothing else company-scheduled is confirmed before it.
• 2026-12-31 (company target) — full balance-sheet portfolio on-chain, per the 2026-07-07 announcement. The date the tokenization claim gets graded against.

Elapsed catalysts

• 2026-08-17 — $100M share repurchase program commences (authorized 2026-08-13). First mechanical bid since the print. (passed 9d ago)
• Ongoing from 2026-08-04 — depositions in the defamation action against Coventry First and chairman Alan Buerger in U.S. District Court. Headline risk in both directions, no scheduled ruling date. (passed 22d ago)

What Would Change Our Mind

The repurchase program is the near-term test that matters: it starts 2026-08-17 with a $100M authorization behind it, and if a company buying its own stock cannot stop the sequence of lower weekly lows through September, the marginal bid is not there at any narrative price. A weekly close below $9.00 confirms post-print distribution and gives up the flat three-month shelf; that is the gradeable break. The secondary breaks are a FY2026 adjusted-EPS guide below $1.00 at the Q3 print, or year-end 2026 arriving with the on-chain portfolio target unmet and no named custody partner.

What would flip the read the other way is equally specific: a weekly close back above $10.50 following a higher low, or a disclosed revenue line attached to the tokenized book rather than a policy count. A single up-day on the buyback start date is not that.

Correlation Notes

• Ticker collision is the first-order screening risk: ABX on NYSE is Abacus Global Management, life settlements. Barrick's legacy ABX now trades as GOLD, and Abaxx Technologies is ABXXF. Gold-tape correlation attributed to this name is a data error.
• Fundamental drivers are mortality/actuarial and rate-linked — policy IRRs and longevity-fund fundraising both move with the discount-rate backdrop — so cash-flow correlation to equity indices is low while the float still trades like a small-cap financial on risk appetite.
• Sentiment correlation runs through the RWA-tokenization complex: the July leg was priced off that theme, so crypto and digital-asset risk appetite is a second channel into the multiple independent of results.